Blood Adv: Increased infection after treatment with myelin HCT in patients with CR1 AML

It is estimated that the reduction of intensity/non-myelin therapy (RIC/NMA) for alloblastation (alloHCT) is low compared to myelin therapy (MAC);in the study of the International Blood and Bone Marrow Transplant Research Center, 1,755 patients with acute myeloid leukemia who were completely remissioned for the first time (age s.40 years) were assessed for infection within 100 days of The Complete Isalooph HCT of T-cellsresults showed that patients receiving RIC/NMA (n s 777) received RIC/NMA had older age and had a shorter transplant period than those receiving MAC (n s978), however, the two groups had similar performance scores, HCT complications index, and cellular genetic risk in Karnofsky1045 (59.5%) patients (MAC, 595 ,61%; RIC/NMA, 450 (58%);P s.21), one or more infections occurred by the 100th dayThe median time at which the initial infection after MAC conditioning occurs is earlier (MAC, 15 days , 1-99 days); RIC/NMA, 21 days (range, 1-100 days) ;P.001)Patients receiving MAC are more likely to experience at least 1 bacterial infection by the 100th day (MAC, 46% of the confidence interval (CI), 43-49); RIC/NMA, 37% of the (95% CI, 34-41) ;Pat least one virus infection is more common in RIC/NMA queues (MAC, 34% of the (95% CI, 31-37); RIC/NMA, 39% of the ;Pmultivariate analysis showed that MAC remained a risk factor for bacterial infection (relative risk, 1.44; 95% CI, 1.23-1.67; PIn addition, the incidence of any infection risk (infection density) per patient-day was greater in the MAC queue during the first 100 days after alloHCT (1.21; 95% CI, 1.11-1.32; P .0001)In the first 100 days after alloHCT, RIC/NMA was associated with a decrease in infections, especially bacterial infections